Skip Navigation



JAC Advance Access published online on April 19, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl138
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/6/1024    most recent
dkl138v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wise, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wise, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Leading article

Antimicrobial resistance: paradox, actions and economics

Richard Wise 1 *

1 Chair, Specialist Advisory Committee on Antimicrobial Resistance, C/O Expert Advisory Support Group, Health Protection Agency Headquarters, 61 Colindale Avenue, London NW9 5HT, UK

* To whom correspondence should be addressed.
Richard Wise, E-mail: r.wise{at}bham.ac.uk


  Abstract

The threat from antimicrobial-resistant organisms is accumulating and accelerating. One strand of the action that an adequate response to this threat demands is good clinical governance through management and audit of antimicrobial prescribing in hospitals. This is the subject of another article in this issue of the Journal, which describes the guidelines developed by the Scottish Medicines Consortium and Scottish Health Executive to tackle this problem. However, the problems posed by resistant organisms are wider still. In a period of increased threat, innovation (new drugs and technologies) seems to be in decline. There are grounds for serious concern that the current economic model is not capable of responding adequately. Governments need to acknowledge and address this fact. Patient outcomes will suffer increasingly if governments do not act to change the status quo.

Keywords: antibiotic policy; prescribing practice; resistance.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.